• OVPR

    The Office of the Vice President for Research facilitates collaborative research opportunities, streamlines related policies and procedures, and acts as a unified voice for U of I research.

  • UIC OTM

    The Office of Technology Management at Chicago is responsible for managing the intellectual property generated by research and educational activities at the University.

  • UIC Research Center

    Supplies a fully-equipped infrastructure and access to University resources, internship programs, world-class talent, and custom-designed business development services.

  • UI Research Park

    Provides an ideal environment for starting a high-growth technology venture, with wet-chemistry labs, office space, an array of shared equipment, server co-location facilities, and conference rooms.

  • IllinoisVENTURES

    IllinoisVENTURES is a seed and early-stage technology investment firm focused on research-derived companies in information technologies, physical sciences and life sciences, with a particular emphasis on those deriving from research conducted at the University of Illinois and other regional research institutions and federal laboratories.

Office of Technology Management, Urbana-Champaign

Novel therapeutic agents for the treatment of hepatitis C virus infection by inhibiting NPC1L1

Therapeutic
Antiviral

Hepatitis C is a blood‐borne infectious disease that is caused by the Hepatitis C virus (HCV), affecting the liver. The infection is often asymptomatic, but once established, chronic infection can cause inflammation of the liver (chronic hepatitis). This condition can progress to scarring of the liver (fibrosis), and advanced scarring (cirrhosis). In some cases, those with cirrhosis will go on to develop liver failure or other complications of cirrhosis, including liver cancer. An estimated 150‐200 million people worldwide are infected with hepatitis C. A major obstacle in the treatment of HCV‐related disease has been the lack of effective, well tolerated therapeutics.

 

Description/Details

The present UIC invention is a novel use or indication for an anti-obesity drug for treatment of hepatitis C virus infection. Hepatitis C virus infection causes a blood-borne infectious disease. The market is at a development stage and has a large patient population with unmet medical needs, and thus is expected to grow to a to $3,554.1 million market by 2011.

 

Applications

• Used in the treatment of chronic, post-exposure, post-transplant, prophylactic hepatitis C virus infection.

Benefits

• The anti-obesity drug is FDA approved.

Inventor Name

Susan Uprichard

Reference #

DC012
print